Colin Bristow
Stock Analyst at UBS
(1.17)
# 3,629
Out of 4,900 analysts
99
Total ratings
34.48%
Success rate
-12.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $12 → $5 | $3.05 | +63.93% | 3 | Jun 17, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $1.2 → $1 | $0.47 | +113.31% | 6 | May 21, 2025 | |
| IMVT Immunovant | Downgrades: Neutral | $38 → $17 | $18.59 | -8.55% | 6 | Apr 22, 2025 | |
| AMGN Amgen | Maintains: Neutral | $315 → $319 | $297.03 | +7.40% | 9 | Apr 14, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $6 → $4 | $1.49 | +168.46% | 4 | Mar 28, 2025 | |
| ENGN enGene Holdings | Downgrades: Neutral | $34 → $7 | $3.34 | +109.58% | 2 | Feb 14, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $586 → $583 | $472.35 | +23.43% | 14 | Feb 11, 2025 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $25.35 | +10.45% | 13 | Feb 5, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $125 → $120 | $83.67 | +43.42% | 6 | Jan 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $47 → $71 | $49.46 | +43.55% | 3 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $96 | $112.09 | -14.35% | 3 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $234 → $202 | $133.11 | +51.75% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $2.02 | +692.08% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $570.59 | +92.61% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $19.23 | +768.43% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $799.34 | -47.46% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $3.93 | -49.11% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.69 | +387.80% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $191.52 | -23.77% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $47.34 | +58.43% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $2.38 | +992.44% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $6.43 | +39.97% | 1 | Aug 23, 2021 |
Rocket Pharmaceuticals
Jun 17, 2025
Maintains: Buy
Price Target: $12 → $5
Current: $3.05
Upside: +63.93%
ALX Oncology Holdings
May 21, 2025
Maintains: Buy
Price Target: $1.2 → $1
Current: $0.47
Upside: +113.31%
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38 → $17
Current: $18.59
Upside: -8.55%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315 → $319
Current: $297.03
Upside: +7.40%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $1.49
Upside: +168.46%
enGene Holdings
Feb 14, 2025
Downgrades: Neutral
Price Target: $34 → $7
Current: $3.34
Upside: +109.58%
Vertex Pharmaceuticals
Feb 11, 2025
Maintains: Buy
Price Target: $586 → $583
Current: $472.35
Upside: +23.43%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $25.35
Upside: +10.45%
Merck & Co.
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $83.67
Upside: +43.42%
PTC Therapeutics
Dec 3, 2024
Maintains: Buy
Price Target: $47 → $71
Current: $49.46
Upside: +43.55%
Nov 21, 2024
Maintains: Neutral
Price Target: $70 → $96
Current: $112.09
Upside: -14.35%
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $133.11
Upside: +51.75%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $2.02
Upside: +692.08%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $570.59
Upside: +92.61%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $19.23
Upside: +768.43%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $799.34
Upside: -47.46%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $3.93
Upside: -49.11%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $3.69
Upside: +387.80%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $191.52
Upside: -23.77%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $47.34
Upside: +58.43%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $2.38
Upside: +992.44%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $6.43
Upside: +39.97%